TVGN
HEALTHCARETevogen Bio Holdings Inc
$7.07-0.30 (-4.07%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving TVGN Today?
No stock-specific AI insight has been generated for TVGN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.14$75.50
$7.07
Fundamentals
Market Cap$30M
P/E Ratio—
EPS$-8.00
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume9K
Avg Volume (10D)—
Shares Outstanding4.2M
TVGN News
20 articles- Tevogen (TVGN) Soars 11% as Firm Gears Up for AI Training CommercializationYahoo Finance·May 5, 2026
- Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application PortalYahoo Finance·Apr 27, 2026
- Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue GrowthYahoo Finance·Mar 26, 2026
- Tevogen Regains Compliance with Nasdaq Minimum Bid Price RequirementYahoo Finance·Mar 25, 2026
- Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)Yahoo Finance·Mar 18, 2026
- Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share UtilizationYahoo Finance·Mar 13, 2026
- Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI InfrastructureYahoo Finance·Mar 13, 2026
- Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care PlatformYahoo Finance·Mar 11, 2026
- Tevogen Names Leadership Team to Execute Diversified Growth StrategyYahoo Finance·Mar 9, 2026
- Letter to Shareholders from CEO Dr. Ryan SaadiYahoo Finance·Mar 6, 2026
- Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal PharmaceuticalYahoo Finance·Mar 5, 2026
- Tevogen Announces Reverse Stock SplitYahoo Finance·Mar 4, 2026
- Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research OrganizationYahoo Finance·Feb 27, 2026
- UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform ClinicusYahoo Finance·Feb 26, 2026
- Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform ClinicusYahoo Finance·Feb 26, 2026
- Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to ShareholdersYahoo Finance·Jan 30, 2026
- Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including RevenueYahoo Finance·Jan 29, 2026
- Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025Yahoo Finance·Jan 12, 2026
- Tevogen CEO Donates Shares to Support Education for Underprivileged ChildrenYahoo Finance·Dec 22, 2025
- Tevogen CEO Donates Personal Shares to Support Local Fire DepartmentYahoo Finance·Dec 19, 2025
All 20 articles loaded
Price Data
Open$7.27
Previous Close$7.37
Day High$7.27
Day Low$6.84
52 Week High$75.50
52 Week Low$4.14
52-Week Range
$4.14$75.50
$7.07
Fundamentals
Market Cap$30M
P/E Ratio—
EPS$-8.00
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume9K
Avg Volume (10D)—
Shares Outstanding4.2M
About Tevogen Bio Holdings Inc
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. The company is headquartered in Warren, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—